PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31697310-1	2020	Importance: Axicabtagene ciloleucel, an anti-CD19-CD28-CD3zeta chimeric antigen receptor T-cell therapy, was the first US Food and Drug Administration-approved, genetically engineered T-cell therapy for adults with relapsed or refractory large B-cell lymphoma (LBCL) after 2 or more lines of systemic therapy.	ciloleucel	25-35	CD28 molecule	Homo sapiens	50-54